Praxis Precision Medicines (PRAX) Current Deferred Revenue (2022 - 2024)

Praxis Precision Medicines' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $1.2 million for Q3 2024.

• In Q3 2024, Current Deferred Revenue fell 24.61% year-over-year to $1.2 million; the TTM figure through Sep 2024 stood at $1.2 million (down 24.61% YoY), while the FY2023 annual figure was $1.4 million, down 72.16% from the prior year.
• Current Deferred Revenue for Q3 2024 stood at $1.2 million, down from $1.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $5.0 million in Q4 2022, with the low at $1.2 million in Q3 2024.
• The 3-year median for Current Deferred Revenue is $1.5 million (2023), against an average of $2.0 million.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue sank 72.16% in 2023, then decreased 24.61% in 2024.
• Praxis Precision Medicines' Current Deferred Revenue stood at $5.0 million in 2022, then tumbled by 72.16% to $1.4 million in 2023, then decreased by 15.95% to $1.2 million in 2024.
• Business Quant data shows PRAX's Current Deferred Revenue at $1.2 million in Q3 2024, $1.2 million in Q2 2024, and $1.3 million in Q1 2024.